ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CANF Can Fite BioPharma Ltd

1.98
0.06 (3.13%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Can Fite BioPharma Ltd AMEX:CANF AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.06 3.13% 1.98 2.01 1.91 1.94 8,665 01:00:00

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

01/02/2021 12:05pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of February 2021

 

001-36203

(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F  þ  Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

The first paragraph of the press release attached to this Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333-195124, 333-236064, 333-209037 and 333-249063), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

 

 

On February 1, 2021, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies”. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

1

 

 

Exhibit Index

 

Exhibit No.   Description
99.1     Press Release dated February 1, 2021

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: February 1, 2021 By: /s/ Pnina Fishman
    Pnina Fishman
    Chief Executive Officer

 

 

 

3

 

1 Year Can Fite BioPharma Chart

1 Year Can Fite BioPharma Chart

1 Month Can Fite BioPharma Chart

1 Month Can Fite BioPharma Chart

Your Recent History

Delayed Upgrade Clock